Showing 40,081 - 40,100 results of 103,787 for search '(( 2 fold decrease ) OR ( 5 ((((mean decrease) OR (a decrease))) OR (teer decrease)) ))', query time: 1.73s Refine Results
  1. 40081
  2. 40082

    Thermodynamic parameters. by Jianqing Jia (21001506)

    Published 2025
    “…Consequently, tunnel reliability decreases. Specifically, with temperature increases of 2.6 °C and 4 °C, tunnel reliability decreases by approximately 4.5% and 6.3%, respectively, when considering insulation layer deterioration.…”
  3. 40083
  4. 40084

    Laboratory surrogate markers of residual HIV replication among distinct groups of individuals under antiretroviral therapy by Leila Bertoni Giron (6848399)

    Published 2019
    “…Lower antibody and LPS levels among patients with initial PI-r ART suggest these regimens may more effectively suppress HIV and have a higher capacity to decrease the HIV antigenic component.…”
  5. 40085
  6. 40086

    Stability and C–H Bond Activation Reactions of Palladium(I) and Platinum(I) Metalloradicals: Carbon-to-Metal H‑Atom Transfer and an Organometallic Radical Rebound Mechanism by Tobias Krämer (1350849)

    Published 2023
    “…One-electron oxidation of palladium(0) and platinum(0) bis(phosphine) complexes enables isolation of a homologous series of linear d<sup>9</sup> metalloradicals of the form [M(PR<sub>3</sub>)<sub>2</sub>]<sup>+</sup> (M = Pd, Pt; R = <i>t</i>Bu, Ad), which are stable in 1,2-difluorobenzene (DFB) solution for >1 day at room temperature when partnered with the weakly coordinating [BAr<sup>F</sup><sub>4</sub>]<sup>−</sup> (Ar<sup>F</sup> = 3,5-(CF<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>) counterion. …”
  7. 40087

    Stability and C–H Bond Activation Reactions of Palladium(I) and Platinum(I) Metalloradicals: Carbon-to-Metal H‑Atom Transfer and an Organometallic Radical Rebound Mechanism by Tobias Krämer (1350849)

    Published 2023
    “…One-electron oxidation of palladium(0) and platinum(0) bis(phosphine) complexes enables isolation of a homologous series of linear d<sup>9</sup> metalloradicals of the form [M(PR<sub>3</sub>)<sub>2</sub>]<sup>+</sup> (M = Pd, Pt; R = <i>t</i>Bu, Ad), which are stable in 1,2-difluorobenzene (DFB) solution for >1 day at room temperature when partnered with the weakly coordinating [BAr<sup>F</sup><sub>4</sub>]<sup>−</sup> (Ar<sup>F</sup> = 3,5-(CF<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>) counterion. …”
  8. 40088

    Distribution of the ΔNPP-to-ΔMAT ratio in relation to MAT and MAP under the current climate. by Jumpei Toriyama (10156884)

    Published 2021
    “…<p>Results from (A) MIROC5 and (B) GFDL-CM3, based on the RCP2.6 scenario. …”
  9. 40089
  10. 40090
  11. 40091

    Image2_The eNAMPT/TLR4 inflammatory cascade drives the severity of intra-amniotic inflammation in pregnancy and predicts infant outcomes.JPEG by Mohamed Ahmed (376976)

    Published 2023
    “…Increased NAMPT expression in whole blood from VLBW neonates (day 5) significantly predicted BPD development. Compared to untreated LPS-challenged murine dams (gestational day 15), pups born to eNAMPT mAb-treated dams (gestational days 15/16) exhibited a > 3-fold improved survival, reduced neonate lung eNAMPT/cytokine levels, and reduced development and severity of BPD and pulmonary hypertension (PH) following postnatal exposure to 100% hyperoxia days 1–14. …”
  12. 40092

    Image_2_A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.tif by James J. Harding (12415627)

    Published 2022
    “…Adult patients with treatment-refractory solid tumors received PF-06671008 (1.5–400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle. …”
  13. 40093

    Image_1_A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.tif by James J. Harding (12415627)

    Published 2022
    “…Adult patients with treatment-refractory solid tumors received PF-06671008 (1.5–400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle. …”
  14. 40094
  15. 40095
  16. 40096
  17. 40097
  18. 40098
  19. 40099
  20. 40100